ICML 2021 | CALGB 50801: PET adapted therapy in bulky stage I/II HL
Ann LaCasce, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA, summarizes the findings from the Phase II CALGB 50801 trial (NCT01118026) assessing positron emission tomography (PET)-adapted therapy in bulky stage I/II classic Hodgkin lymphoma. Patients initially received ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) treatment. Patients who subsequently had a PET2- scan received further ABVD treatment without radiotherapy, whereas patients with a PET2+ scan received BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) with radiotherapy. Patients with PET2- scans had a good outcome with a high progression-free survival rate, avoiding the late toxicities associated with radiotherapy, and patients with PET2+ scans had similar outcomes. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
